April 2025 – Page 5 – schizophrenia

Discover how schizophrenia affects work life, and explore strategies for obtaining work accommodations, establishing support, and maintaining employment.

Apr 08 2025

Uncategorized

Maniac who slashed his 4 nieces with meat cleaver in NYC clinging to life — as sources revealed he suffers from schizophrenia

by Clinical Editor

No Comments

The Brooklyn maniac who brutally slashed four young girls with a meat cleaver is still clinging to life after undergoing emergency surgery – as sources revealed that he had been...

Apr 08 2025

Uncategorized

Hope, caution for Washington state patients ‘first in line’ for new schizophrenia drug

by Clinical Editor

No Comments

Cobenfy was approved by the Food and Drug Administration in fall 2024 and represents the first novel approach in decades to treating schizophrenia, which affects an estimated 3.7 million American...

Apr 07 2025

Uncategorized

Hope, caution for WA patients ‘first in line’ for new schizophrenia drug

by Clinical Editor

No Comments

Washingtonians with schizophrenia are curious about a recently FDA-approved drug to treat their symptoms but much is unknown about how well it works.

Apr 07 2025

Uncategorized

Insights on Schizophrenia-Linked Hoarding

by Clinical Editor

No Comments

A recent study of the hoarding phenomenon within schizophrenia spectrum disorders highlights the need for nuanced assessments and reconsideration of diagnostic classifications.

Apr 06 2025

Uncategorized

Glutamate and Psychiatric Disorders

by Clinical Editor

No Comments

Discover how the brain’s most abundant neurotransmitter, glutamate, is revolutionizing psychiatry and offering new hope for depression, bipolar disorder, and more.

Apr 05 2025

Uncategorized

New global guidelines to treat schizophrenia

by Clinical Editor

No Comments

New guidelines have been developed for the treatment of schizophrenia through a collaborative effort of international experts from 30 countries. The recommendations are published in The Lancet …

Apr 04 2025

Uncategorized

Teva’s Novel Schizophrenia Drug Candidate Demonstrates High Patient, Provider Satisfaction in Phase III Trial Survey

by Clinical Editor

No Comments

Results from the SOLARIS trial survey showed that over 92% of patients, 87% of nurses, and 72% of physicians expressed satisfaction with TEV-‘749’s initiation regimen, dosing schedule, and overall …

Month: April 2025